Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

Allogeneic transplant (alloHCT) and chimeric antigen receptor modified (CAR)-T cell therapy are potentially cuarative options of diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous (auto)HCT. Although the Center for International Blood and Marrow Transplant Research (CIBMTR) prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamadani, Mehdi, Gopal, Ajay K., Pasquini, Marcelo, Kim, Soyoung, Qiu, Xianmiao, Ahmed, Sairah, Lazaryan, Aleksandr, Bhatt, Vijaya Raj, Daly, Andrew, Lulla, Premal, Ciurea, Stefan, Gauthier, Jordan, Agrawal, Vaibhav, Grover, Natalie S., Lekakis, Lazaros, Modi, Dipenkumar, Dahi, Parastoo B., Herr, Megan M., Johnson, P. Connor, Hashmi, Hamza, Hematti, Peiman, Locke, Frederick L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791562/
https://www.ncbi.nlm.nih.gov/pubmed/34673903
http://dx.doi.org/10.1182/bloodadvances.2021005788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791562/
https://www.ncbi.nlm.nih.gov/pubmed/34673903
http://dx.doi.org/10.1182/bloodadvances.2021005788

Ejemplares similares